Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
The Healthy on MSN2d
These Are 12 Silent Symptoms of a Heart Attack, According to Cardiologists
Chest pain or pressure, cold sweat, extreme weakness—you know those heart attack signs. But there are more subtle symptoms ...
Woman, 23, had a ‘burning sensation' in her stomach. It was the first sign of a rare cancer
In 2023, Sydney Towle, then 23, developed a bump on her abdomen that she could feel. When she exercised, she experienced a ...